PharmaVoice
AUGUST 18, 2022
Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.
Pharmacy Times
AUGUST 18, 2022
Analysis is based on functional magnetic resonance imaging to provide insight into the effective connectivity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 18, 2022
Endo International is the latest drugmaker to file for chapter 11 bankruptcy protection in connection with opioid litigation in the US, after agreeing a $6 billion deal with creditors that includes an offer to settle outstanding lawsuits. The Ireland-domiciled company is struggling under the weight of around $8 billion in debt, and has been hamstrung by costs associated with fighting thousands of suits that accuse it of wrongdoing in its marketing and promotion of painkiller Opana ER (oxymorphon
Pharmacy Times
AUGUST 18, 2022
A study suggests the paradigm of retail pharmacy is shifting, as customers are wanting more health and wellness-centered pharmacies as well as digital services.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
AUGUST 18, 2022
The US Food and Drug Administration (FDA) has granted approval for bluebird bio ’s Zynteglo (betibeglogene autotemcel, beti-cel) for the treatment of the underlying genetic cause of beta?thalassemia in adult and paediatric patients. A custom-made, one-dose gene therapy, Zynteglo is indicated for such patients who need red blood cells (RBCs) transfusions on a regular basis.
Pharmacy Times
AUGUST 18, 2022
In a recent survey, community pharmacists discussed current hardships in the industry, which include low supply, increasing costs, and trouble filling necessary positions.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
AUGUST 18, 2022
Adalimumab-bwwd is a tumor necrosis factor blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis.
European Pharmaceutical Review
AUGUST 18, 2022
The US Food and Drug Administration (FDA) has approved bluebird bio’s Zynteglo (betibeglogene autotemcel; beti-cel), the first cell-based gene therapy for the treatment of adult and paediatric patients with beta-thalassemia who require regular red blood cell transfusions. . “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing red blood cell transfusions,” commented Peter Marks, MD PhD, director of the FDA’s Center for Bio
Pharmacy Times
AUGUST 18, 2022
Dr. Christina Madison, The Public Health Pharmacist, was recently on Good Morning America discussing the do's and don'ts of expired medications.
pharmaphorum
AUGUST 18, 2022
As Frontiers Health approaches, we’re featuring interviews with members of the steering committee to give you a sneak peek of what to expect in Milan. Interested in signing up? pharmaphorum readers get a discount through this link. Though the field is still young, digital therapeutics are no longer a brand-new technology. Many different DTx offerings are in the field, being used by patients and prescribed by physicians, backed by rigorous scientific evidence.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
AUGUST 18, 2022
The U.S. Health System can be difficult to navigate and creates barriers, which is why speaking up as health care professionals is extremely important.
PharmExec
AUGUST 18, 2022
Richard Young, Vice President of Strategy, Vault CDMS and Tim Davis, Vice President of Strategy, MyVeeva for Patients, discuss the future of digital trials and their impact in the industry.
Pharmacy Times
AUGUST 18, 2022
Investigators reported that people who frequently naps may have an increased risk of high blood pressure and ischemic stroke by 12% compared to people who do not nap.
NICE
AUGUST 18, 2022
Over the last 12 months, NICE has been working with the Care Quality Commission, Health Research Authority and Medicines and Healthcare products Regulatory Agency to develop a multi-agency advisory service for artificial intelligence (AI) and digital technologies in health and care (MAAS). Expected to launch next year, the MAAS will enable the development and widespread adoption of value-adding technologies, optimising care and improving outcomes across the health and care system.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
AUGUST 18, 2022
Ganciclovir injection is a nucleoside analogue cytomegalovirus DNA polymerase inhibitor.
Outsourcing Pharma
AUGUST 18, 2022
The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients.
Pharmacy Times
AUGUST 18, 2022
For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel increased their rate of survival after 1 year by nearly 30%.
pharmaphorum
AUGUST 18, 2022
Astellas remains on course to be the first drugmaker to bring a new non-hormonal therapy for symptoms of menopause to market, after the FDA started a review of its orally-active neurokinin-3 (NK3) receptor antagonist fezolinetant. The US regulator is scheduled to complete its review of fezolinetant as a treatment for moderate to severe vasomotor symptoms (VMS) of menopause, such as hot flushes and night sweats, by 22 February next year, said the Japanese pharma.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
AUGUST 18, 2022
Uric Acid Cleanse helps to managing uric acid levels for kidney support.
pharmaphorum
AUGUST 18, 2022
UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently-approved therapy for two forms of ANCA-associated vasculitis (AAV) – oral complement C5 inhibitor Tavneos – which will be launched in the next few weeks. CSL Vifor – which licenses Tavneos (avacopan) from US biotech ChemoCentryx – announced the decision on behalf Vifor Fresenius Medical Care Renal Pharma, its joint venture with Fresenius, which will market the drug in the UK.
Pharmacy Times
AUGUST 18, 2022
Each year, the NCPA Annual Convention is able to showcase student business plans in a competition that correlates to a real life business plan.
pharmaphorum
AUGUST 18, 2022
Researchers also dove into socio-economic disparities in cancer care. Last month in Chicago, Illinois the American Society of Clinical Oncology hosted its first in-person meeting since the COVID-19 pandemic began. In presentations and published abstracts, researchers shared a massive amount of data across all cancer types and treatment modalities. Below are just a few of the highlights from the show.
Pharmacy Times
AUGUST 18, 2022
Study results show a compound annual growth rate of 5.2% from $392.4 billion in revenue in 2021.
Pharmaceutical Commerce
AUGUST 18, 2022
Company’s 344,000 square-foot facility revolves around pharma and medical items.
Pharmacy Times
AUGUST 18, 2022
This month's product news includes women's wellness supplements, menstrual pain relief cream, and mineral sunscreen.
PharmExec
AUGUST 18, 2022
Raj Verma, chief diversity, culture, and experience officer at Sanofi, discusses the various ways people see diversity around the world and how companies should be building diversity, equity, and inclusion into a company’s everyday fabric.
Pharmacy Times
AUGUST 18, 2022
Survey results reflect positive sentiments from older adults for the proposed Equitable Community Access to Pharmacist Services Act.
PharmExec
AUGUST 18, 2022
There are several strategies life sciences companies can use to benefit from biosimilars.
Pharmacy Times
AUGUST 18, 2022
The drug also meets the key secondary endpoint of improved overall survival for treatment for individuals with HER2 positive unresectable and/or metastatic breast cancer.
pharmaphorum
AUGUST 18, 2022
bluebird bio’s Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require regular blood transfusions. The US approval comes three years after Zynteglo (betibeglogene autotemcel) was approved for the same indication in Europe, and subsequently withdrawn after bluebird concluded that it wasn’t possible to build a commercially viable business for the gene therapy as the prici
Pharma Times
AUGUST 18, 2022
Therapy for the treatment of myelofibrosis has received significant results from phase 3 trial
Pharmaceutical Commerce
AUGUST 18, 2022
Partnership adds technological offerings to PharmaLex’s repertoire.
Pharma Times
AUGUST 18, 2022
The SMC approval brings much-needed boost to asthma sufferers across Scotland
Expert insights. Personalized for you.
262 
Let's personalize your content